-+ 0.00%
-+ 0.00%
-+ 0.00%

Can-Fite advances Namodenoson into Phase 2b pancreatic cancer immunotherapy combination trial

PUBT·05/13/2026 11:01:14
Listen to the news
Can-Fite advances Namodenoson into Phase 2b pancreatic cancer immunotherapy combination trial
  • Can-Fite BioPharma plans Phase 2b clinical trial testing Namodenoson combined with immunotherapy in advanced pancreatic cancer.
  • Move follows Phase 2a results already presented from patients previously treated for pancreatic adenocarcinoma, showing a favorable safety profile with signs of disease control in some patients.
  • Phase 2b aims to confirm clinical benefit, with focus on survival and disease stabilization outcomes.
  • Study design will be presented in future at BIO International Convention in San Diego, alongside ongoing partnership talks with oncology drugmakers under confidentiality agreements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130700PRIMZONEFULLFEED9719302) on May 13, 2026, and is solely responsible for the information contained therein.